Oxford Biodynamics plc
Oxford BioDynamics Plc (OBD) is an AIM-listed international biotechnology company commercialising its proprietary EpiSwitch 3D genomics platform for personalised healthcare. It has launched two commercial blood tests – EpiSwitch PSE (prostate cancer screening) and EpiSwitch CiRT (checkpoint inhibitor immunotherapy response) – and also undertakes biomarker discovery and clinical development work for pharma/biotech partners. The Group operates CLIA-accredited and ISO-accredited clinical laboratories in Oxford, UK and Frederick, MD, USA, plus a reference lab in Penang, Malaysia, and is developing a cloud platform, EpiSwitch Orion, on Google Cloud.
FY2025 in sixty seconds
year to 30 Sept 2025 · approved 15 Dec 2025 · 128 pages · Companies House
Oxford BioDynamics sells blood tests that help screen for prostate cancer and predict how patients will respond to cancer treatment. Revenue rose 72.2% to £1.1m, while the loss after tax narrowed slightly to £11.2m from £11.6m.
Growth came mainly from the prostate test, whose orders more than doubled. Income from research work for drug companies fell to nothing. Job cuts and lower marketing and travel spending reduced costs. The loss included one-off costs, among them a write-down in the value of some patents and a payment to the departing chief executive.
The company ended the year with £1.4m of cash (previous year £1.8m) and no borrowings, after raising £7.4m from shareholders. It paid no dividend, and it raised a further £7m after the year end. Management said its turnaround is progressing and aims to sign partnership or licensing deals for its tests, though none had been agreed. The auditor pointed to a material uncertainty, meaning real doubt, over whether the company can keep going without raising more money. Without licensing income, that money could be needed as early as the third quarter of 2026.
EpiSwitch PSE prostate screening test orders
PSE orders more than doubled year-on-year to ~1,900 (FY24: ~725); monthly orders grew from under 100 in Sept 2024 to 215 in Sept 2025, with 250 orders in November 2025
page 2Sales approach shift to employed managers plus commission-only contractors in the US
Enabled sales growth without materially increasing the fixed cost base
page 6Executive Chairman states the 'turnaround is progressing', with PSE orders growing, cost-saving initiatives implemented, and the aim to establish CiRT in NCCN guidelines; third-party partnering/licensing discussions ongoing but no deal concluded as at report date
page 4No dividends declared or proposed for FY25 (2024: £nil); stated intention is to create value for investors 'eventually through dividend payments'
page 1211 years on one page · FY2015–FY2025
| Line | FY2015locked | FY2016locked | FY2017locked | FY2018locked | FY2019locked | FY2020locked | FY2021locked | FY2022locked | FY202309/23 | FY202409/24 | FY202509/25 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||
| Operating profit | |||||||||||
| Profit for the year | |||||||||||
| Basic EPS | |||||||||||
| Dividend per share | — | ||||||||||
| Free cash flow | |||||||||||
| Net debt (negative = net cash) | |||||||||||
| Shares in issue | |||||||||||
| Operating margin | |||||||||||
| Return on capital employed |
GBP millions, negatives in brackets. Per-share lines in pence. Share counts in millions. Margins and returns as percentages, calculated from the filed figures. later is what a following report restated the figure to; vs is a second reading that disagrees. The figure shown is the one the original filing printed, and both readings are kept. Click any figure: opens the report page it was read from, highlighted; shows how it was calculated.
9 figures restated in a later report
Every figure is read again from the following year’s report: 332 confirmed, 6 differ, 9 restated.
No figure has been restated: every figure a later report printed again, it printed the same.
9 more figures were restated in FY2015 to FY2022, which a free account opens.